MyStocks

MEMBER'S LOGINX

Remember Username
Keep me signed in

(Please do not use this option on a public machine)

Home
Research It
Compare Company
International - pharmaceuticals
ASTRAZENECA PHARMA - MYLAN (US)

ASTRAZENECA PHARMA vs MYLAN (US) - Comparison Results

Mail
Print
FaceBook
Twitter
Linked In
WhatsApp

ASTRAZENECA PHARMA Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

MYLAN (US)
Change

Mylan is one of the world�s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry�s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

ASTRAZENECA PHARMA

MYLAN

EQUITY SHARE DATA
		ASTRAZENECA PHARMA Mar-18	MYLAN Dec-18	ASTRAZENECA PHARMA/ MYLAN	5-Yr Chart Click to enlarge
High	Rs	1,278	3,410	-
Low	Rs	883	1,877	-
Sales per share (Unadj.)	Rs	228.4	1,568.9	-
Earnings per share (Unadj.)	Rs	10.4	42.6	-
Cash flow per share (Unadj.)	Rs	16.3	336.4	-
Dividends per share (Unadj.)	Rs	0	0	-
Dividend yield (eoy)	%	0	0	-
Book value per share (Unadj.)	Rs	98.8	1,697.3	-
Shares outstanding (eoy)	m	25.00	514.50	-
Bonus/Rights/Conversions		-	-	-
Price / Sales ratio	x	4.7	1.7	280.8%
Avg P/E ratio	x	104.2	62.0	168.0%
P/CF ratio (eoy)	x	66.4	7.9	845.5%
Price / Book Value ratio	x	10.9	1.6	702.3%
Dividend payout	%	0	0	-
Avg Mkt Cap	Rs m	27,008	1,359,899	2.0%
No. of employees	`000	1.4	35.0	3.9%
Total wages/salary	Rs m	1,535	0	-
Avg. sales/employee	Rs Th	4,210.9	23,062.8	18.3%
Avg. wages/employee	Rs Th	1,132.2	0	-
Avg. net profit/employee	Rs Th	191.1	626.3	30.5%

INCOME DATA
Net Sales	Rs m	5,710	807,198	0.7%
Other income	Rs m	123	0	-
Total revenues	Rs m	5,833	807,198	0.7%
Gross profit	Rs m	463	208,873	0.2%
Depreciation	Rs m	147	151,139	0.1%
Interest	Rs m	0	38,823	0.0%
Profit before tax	Rs m	438	18,910	2.3%
Minority Interest	Rs m	0	0	-
Prior Period Items	Rs m	0	0	-
Extraordinary Inc (Exp)	Rs m	0	0	-
Tax	Rs m	179	-3,008	-5.9%
Profit after tax	Rs m	259	21,919	1.2%
Gross profit margin	%	8.1	25.9	31.3%
Effective tax rate	%	40.8	-15.9	-256.7%
Net profit margin	%	4.5	2.7	167.1%

BALANCE SHEET DATA
Current assets	Rs m	3,209	450,739	0.7%
Current liabilities	Rs m	2,070	328,638	0.6%
Net working cap to sales	%	20.0	15.1	132.0%
Current ratio	x	1.6	1.4	113.1%
Inventory Days	Days	72	84	86.6%
Debtors Days	Days	35	93	37.4%
Net fixed assets	Rs m	790	156,583	0.5%
Share capital	Rs m	50	430	11.6%
"Free" reserves	Rs m	2,419	0	-
Net worth	Rs m	2,469	873,241	0.3%
Long term debt	Rs m	0	942,508	0.0%
Total assets	Rs m	4,605	2,342,373	0.2%
Interest coverage	x	NM	1.5	-
Debt to equity ratio	x	0	1.1	0.0%
Sales to assets ratio	x	1.2	0.3	359.8%
Return on assets	%	5.6	2.6	217.0%
Return on equity	%	10.5	2.5	418.0%
Return on capital	%	17.7	3.2	557.9%
Exports to sales	%	0	0	-
Imports to sales	%	0	0	-
Net fx	Rs m	-1,715	0	-

CASH FLOW
From Operations	Rs m	88	167,736	0.1%
From Investments	Rs m	-94	-86,701	0.1%
From Financial Activity	Rs m	NA	-78,141	0.0%
Net Cashflow	Rs m	-6	1,390	-0.4%

NM: Not Meaningful

Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.63 Rs / USD

Compare ASTRAZENECA PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)

Compare ASTRAZENECA PHARMA With: FDC LTD. STRIDES PHARMA SCIENCE ABBOTT INDIA SUN PHARMA WYETH LTD